Detects human TRAIL R3/TNFRSF10C in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, and rhTRAIL R2 is observed.
Polyclonal Goat IgG
Mouse myeloma cell line NS0-derived recombinant human TRAIL R3/TNFRSF10C Ala26-Ala221 Accession # O14798
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Immersion fixed paraffin-embedded sections of human brain (occipital cortex) subjected to Antigen Retrieval Reagent-Basic (Catalog # CTS013)
Measured by its ability to neutralize TRAIL R3/TNFRSF10C-mediated inhibition of cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND50) is typically 0.015-0.045 µg/mL in the presence of 20 ng/mL Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera, 12 ng/mL of Recombinant Human TRAIL, and 1 µg/mL actinomycin D.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of Human TRAIL R3/TNFRSF10C by Western Blot. Western blot shows lysates of L‑929 mouse fibroblast cell line, THP‑1 human acute monocytic leukemia cell line, and WS‑1 human fetal skin fibroblast cell line. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human TRAIL R3/TNFRSF10C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF630) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for TRAIL R3/TNFRSF10C at approximately 27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
TRAIL R3/TNFRSF10C Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R3/TNFRSF10C Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (5 µg/mL, Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (Catalog # 630-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375‑TL) induced cytotoxicity in the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/ TNFSF10 (12 ng/mL) activity elicited by Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TRAIL R3/ TNFRSF10C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF630). The ND50 is typically 0.015-0.045 µg/mL.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TRAIL R3/TNFRSF10C
Human TRAIL R3, also called DcR1 (decoy receptor 1), LIT, and TRID, is a glycosyl-phosphatidylinositol-linked membrane protein which binds TRAIL (Apo2 Ligand) with high affinity. In the new TNF superfamily nomenclature, TRAIL R3 is referred to as TNFRSF10C. TRAIL R3 has the TRAIL-binding extracellular cysteine-rich domains but lacks the intracellular signalling domain. As a result, binding of TRAIL to TRAIL R3 does not transduce an apoptosis signal. Expression of TRAIL R3 has been shown to protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-induced apoptosis. A second TRAIL decoy receptor, which binds TRAIL with high-affinity but antagonizes TRAIL-induced apoptosis, named TRAIL R4, DcR2 or TRUNDD, has also been reported. The human soluble TRAIL R3/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.
Sheridan, J.P. et al. (1997) Science 277:818.
Golstein, P. (1997) Curr. Biol. 7:R750.
TRAIL Receptor 3
Entrez Gene IDs:
Antagonist decoy receptor for TRAIL/Apo-2L; CD263 antigen; CD263; cytotoxic TRAIL receptor-3; DcR1; DCR1MGC149502; Decoy receptor 1; Decoy TRAIL receptor without death domain; LITMGC149501; Lymphocyte inhibitor of TRAIL; TNFRSF10C; TRAIL R3; TRAIL receptor 3; TRAIL receptor without an intracellular domain; TRAILR3; TRAIL-R3; TRAILR3TNF-related apoptosis-inducing ligand receptor 3; TRIDDCR1-TNFR; tumor necrosis factor receptor superfamily member 10C; tumor necrosis factor receptor superfamily, member 10c, decoy without anintracellular domain
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.